Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All bamlanivimab/etesevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Hospitalization 39% Bamlanivimab/e..  Corwin et al.  EARLY TREATMENT Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 6,117 patients in the USA (November 2020 - January 2021) Lower hospitalization with bamlanivimab/etesevimab (p=0.00044) c19early.org Corwin et al., Open Forum Infectious D.., Jun 2021 Favors bamlanivimab/e.. Favors control

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting

Corwin et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab305
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
20th treatment shown to reduce risk in May 2021
 
*, now known with p = 0.00029 from 20 studies, recognized in 4 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 780 bamlanivimab patients and 5,337 patients not receiving treatment, showing lower hospitalization and ER visits with treatment.
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene c19early.org, c19early.org (B), vitamin D c19early.org (C), etc.) — either because the physician recommending bamlanivimab/etesevimab also recommended them, or because the patient seeking out bamlanivimab/etesevimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate the efficacy of treatments.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron Haars, Liu, Pochtovyi, Sheward, VanBlargan.
risk of death, 80.5% lower, RR 0.20, p = 0.08, treatment 1 of 780 (0.1%), control 35 of 5,337 (0.7%), NNT 190.
risk of hospitalization, 39.4% lower, RR 0.61, p < 0.001, treatment 57 of 780 (7.3%), control 490 of 5,337 (9.2%), odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Corwin et al., 10 Jun 2021, retrospective, USA, peer-reviewed, 8 authors, study period 23 November, 2020 - 17 January, 2021. Contact: douglas.corwin@sluhn.org.
This PaperBamlaniv../e..All
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
MD Douglas S Corwin, Peter T Ender, Nitasa Sahu, Ryan A Durgham, Dennis M Mcgorry Jr, Awan Rahman, Jill Stoltzfus, Jeffrey A Jahre
Open Forum Infectious Diseases, doi:10.1093/ofid/ofab305
Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 . This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
Author contributions. D.S.C., P.E., N.S., R.D., and J.S. drafted the initial manuscript. All authors reviewed, contributed to the revision and approved the final manuscript. D.S.C. had full access to manuscript and final responsibility to submit for publication.
References
Bowden, Hospitals face severe shortages as pandemic grinds forward. The Hill
Chen, Nirula, Heller, BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Goldhill, Hospitals in half the states are facing a massive staffing shortage, STAT
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Halpin, Criner, Papi, Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD Science Committee report on COVID-19 and chronic obstructive pulmonary disease, Am J Respir Crit Care Med
Jorden, Rudman, Evidence for limited early spread of COVID-19 within the United States, MMWR Morb Mortal Wkly Rep
Kane, Shamliyan, Mueller, Nurse staffing and quality of patient care, Evid Rep Technol Assess (Full Rep)
Leatherby, Keefe, Tompkins, There's no place for them to go': I.C.U. beds near capacity across U.S. The New York Times
O'hearn, Liu, Cudhea, Coronavirus disease 2019 hospitalizations attributable to cardiometabolic conditions in the United States: a comparative risk assessment analysis, J Am Heart Assoc
Wang, Nair, Liu, Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization
Wickham, R packages for data science
Widera, Wilhelm, Hoehl, Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro
{ 'DOI': '10.1093/ofid/ofab305', 'ISSN': ['2328-8957'], 'URL': 'http://dx.doi.org/10.1093/ofid/ofab305', 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Bamlanivimab, a monoclonal antibody targeting the spike protein of ' 'severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of ' 'coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of ' 'bamlanivimab in reducing hospital admissions and emergency department visits among high-risk ' 'outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved ' 'mortality.</jats:p>', 'author': [ { 'affiliation': [ { 'name': 'Section of Pulmonary and Critical Care, Department of Medicine, ' 'St Luke’s University Health Network, Bethlehem, Pennsylvania, ' 'USA'}], 'family': 'Corwin', 'given': 'Douglas S', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Section of Infectious Diseases, Department of Medicine, St. ' 'Luke’s University Health Network, Bethlehem, Pennsylvania, USA'}], 'family': 'Ender', 'given': 'Peter T', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Section of Pulmonary and Critical Care, Department of Medicine, ' 'St Luke’s University Health Network, Bethlehem, Pennsylvania, ' 'USA'}], 'family': 'Sahu', 'given': 'Nitasa', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Temple/St. Luke’s School of Medicine, Bethlehem, Pennsylvania, ' 'USA'}], 'family': 'Durgham', 'given': 'Ryan A', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Family Medicine, St. Luke’s University Health ' 'Network, Bethlehem, Pennsylvania, USA'}], 'family': 'McGorry', 'given': 'Dennis M', 'sequence': 'additional', 'suffix': 'Jr.'}, { 'affiliation': [ { 'name': 'Section of Pulmonary and Critical Care, Department of Medicine, ' 'St Luke’s University Health Network, Bethlehem, Pennsylvania, ' 'USA'}], 'family': 'Rahman', 'given': 'Awan', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Graduate Medical Education, Data Management and Outcomes ' 'Assessment, St. Luke’s University Health Network, Bethlehem, ' 'Pennsylvania, USA'}], 'family': 'Stoltzfus', 'given': 'Jill', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Section of Infectious Diseases, Department of Medicine, St. ' 'Luke’s University Health Network, Bethlehem, Pennsylvania, USA'}], 'family': 'Jahre', 'given': 'Jeffrey A', 'sequence': 'additional'}], 'container-title': 'Open Forum Infectious Diseases', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 6, 10]], 'date-time': '2021-06-10T16:08:25Z', 'timestamp': 1623341305000}, 'deposited': { 'date-parts': [[2021, 7, 11]], 'date-time': '2021-07-11T19:21:36Z', 'timestamp': 1626031296000}, 'indexed': {'date-parts': [[2023, 5, 8]], 'date-time': '2023-05-08T07:50:10Z', 'timestamp': 1683532210332}, 'is-referenced-by-count': 5, 'issue': '7', 'issued': {'date-parts': [[2021, 6, 10]]}, 'journal-issue': {'issue': '7', 'published-print': {'date-parts': [[2021, 7, 1]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 6, 10]], 'date-time': '2021-06-10T00:00:00Z', 'timestamp': 1623283200000}}], 'link': [ { 'URL': 'http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab305/38576790/ofab305.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ofid/article-pdf/8/7/ofab305/38897252/ofab305.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ofid/article-pdf/8/7/ofab305/38897252/ofab305.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'prefix': '10.1093', 'published': {'date-parts': [[2021, 6, 10]]}, 'published-online': {'date-parts': [[2021, 6, 10]]}, 'published-other': {'date-parts': [[2021, 7, 1]]}, 'published-print': {'date-parts': [[2021, 7, 1]]}, 'publisher': 'Oxford University Press (OUP)', 'reference': [ { 'DOI': '10.15585/mmwr.mm6922e1', 'article-title': 'Evidence for limited early spread of COVID-19 within the United States, ' 'January – February 2020', 'author': 'Jorden', 'doi-asserted-by': 'crossref', 'first-page': '680', 'journal-title': 'MMWR Morb Mortal Wkly Rep', 'key': '2021071119212397000_CIT0001', 'volume': '69', 'year': '2020'}, {'key': '2021071119212397000_CIT0002'}, {'author': 'Leatherby', 'key': '2021071119212397000_CIT0003', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2029849', 'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19', 'author': 'Chen', 'doi-asserted-by': 'crossref', 'first-page': '229', 'journal-title': 'N Engl J Med', 'key': '2021071119212397000_CIT0004', 'volume': '384', 'year': '2021'}, { 'DOI': '10.1001/jama.2021.0202', 'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial', 'author': 'Gottlieb', 'doi-asserted-by': 'crossref', 'first-page': '632', 'journal-title': 'JAMA', 'key': '2021071119212397000_CIT0005', 'volume': '325', 'year': '2021'}, {'author': 'Wickham', 'key': '2021071119212397000_CIT0006'}, { 'DOI': '10.1161/JAHA.120.019259', 'article-title': 'Coronavirus disease 2019 hospitalizations attributable to ' 'cardiometabolic conditions in the United States: a comparative risk ' 'assessment analysis', 'author': 'O’Hearn', 'doi-asserted-by': 'crossref', 'first-page': 'e019259', 'journal-title': 'J Am Heart Assoc', 'key': '2021071119212397000_CIT0007', 'volume': '10', 'year': '2021'}, { 'DOI': '10.1164/rccm.202009-3533SO', 'article-title': 'Global initiative for the diagnosis, management, and prevention of ' 'chronic obstructive lung disease. The 2020 GOLD Science Committee ' 'report on COVID-19 and chronic obstructive pulmonary disease', 'author': 'Halpin', 'doi-asserted-by': 'crossref', 'first-page': '24', 'journal-title': 'Am J Respir Crit Care Med', 'key': '2021071119212397000_CIT0008', 'volume': '203', 'year': '2021'}, { 'article-title': 'Nurse staffing and quality of patient care', 'author': 'Kane', 'first-page': '1', 'journal-title': 'Evid Rep Technol Assess (Full Rep)', 'key': '2021071119212397000_CIT0009', 'year': '2007;'}, {'author': 'Goldhill', 'key': '2021071119212397000_CIT0010'}, {'author': 'Bowden', 'key': '2021071119212397000_CIT0011', 'year': '2021'}, {'key': '2021071119212397000_CIT0012', 'year': '2021'}, { 'article-title': 'Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to ' 'antibody neutralization', 'author': 'Wang', 'journal-title': 'bioRxiv', 'key': '2021071119212397000_CIT0013', 'year': '2021'}, { 'article-title': 'Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K ' 'in vitro', 'author': 'Widera', 'journal-title': 'medRxiv', 'key': '2021071119212397000_CIT0014', 'year': '2021'}, { 'DOI': '10.1001/jama.2021.0202', 'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial', 'author': 'Gottlieb', 'doi-asserted-by': 'crossref', 'first-page': '632', 'journal-title': 'JAMA', 'key': '2021071119212397000_CIT0015', 'volume': '325', 'year': '2021'}], 'reference-count': 15, 'references-count': 15, 'relation': {}, 'resource': {'primary': {'URL': 'https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofab305/6295837'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Oncology'], 'subtitle': [], 'title': 'The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a ' 'Real-world Setting', 'type': 'journal-article', 'volume': '8'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit